CLINICAL-LABORATORY, IMMUNOLOGICAL, PATHOGENETIC MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME AND IDENTIFICATION OF EFFECTIVE TREATMENT REGIMENS (REVIEWS)

dc.contributor.author	Musakov Mirzokhid Sabitdjanovich
dc.contributor.author	Samatova Lobar Dilmurodovna
dc.contributor.author	Turaxojaeva Sabokhat Sultanshikovna
dc.contributor.author	Salaeva Muborak Saidabdullayevna
dc.contributor.author	Tursunova Minavvar Ulug’bekovna
dc.date.accessioned	2025-12-28T20:18:21Z
dc.date.issued	2023-05-12
dc.description.abstract	Antiphospholipid syndrome (APS) is one of the leading causes of thrombosis. According to some estimates, the incidence of APS is about 5 new cases per 100,000 people per year and the prevalence is about 40-50 cases per 100,000 people [1], thus the problem of APS remains one of the most important in medicine.
dc.format	application/pdf
dc.identifier.uri	https://sjird.journalspark.org/index.php/sjird/article/view/643
dc.identifier.uri	https://asianeducationindex.com/handle/123456789/13500
dc.language.iso	eng
dc.publisher	Journals Park Publishing
dc.relation	https://sjird.journalspark.org/index.php/sjird/article/view/643/617
dc.source	Spectrum Journal of Innovation, Reforms and Development; Vol. 15 (2023); 51-61
dc.source	2751-1731
dc.subject	antiphospholipid syndrome (APS), antiphospholipid antibodies, lupus anticoagulant.
dc.title	CLINICAL-LABORATORY, IMMUNOLOGICAL, PATHOGENETIC MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME AND IDENTIFICATION OF EFFECTIVE TREATMENT REGIMENS (REVIEWS)
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.type	Peer-reviewed Article

item.page.files

pagination.showing.labelpagination.showing.detail

item.page.filesection.name: sabitdjanovich_2023_clinical-laboratory_immunological_pathog.pdf
item.page.filesection.size: 298.72 KB
item.page.filesection.format: Adobe Portable Document Format